-
Publication Venue For
-
EXTH-96. BIOPROCESSING OF SURGICAL PEDIATRIC BRAIN TUMOR SPECIMENS FOR GENOME-GUIDED PERSONALIZED DRUG TESTING.
24:vii232-vii232.
2022
-
STEM-15. THERAPY-INDUCED CHANGES BY BRAF AND MEK INHIBITORS IN BRAF V600E-MUTATED GLIOMA MODELS PROVIDE POTENTIAL NOVEL THERAPEUTIC OPPORTUNITIES.
24:vii34-vii34.
2022
-
DIPG-15. Major tumor regressions in H3K27M-mutated diffuse midline glioma (DMG) following sequential intravenous (IV) and intracerebroventricular (ICV) delivery of GD2-CAR T-cells.
24:i20-i21.
2022
-
Highlights from the Literature.
23:14-16.
2021
-
BIOM-50. GENETIC PREDISPOSITION TO LONGER TELOMERE LENGTH AND RISK OF CHILDHOOD, ADOLESCENT AND ADULT-ONSET EPENDYMOMA.
22:ii12-ii12.
2020
-
EPCO-13. GENOME-WIDE ASSOCIATION STUDY IN INDIVIDUALS OF ASHKENAZI JEWISH ANCESTRY IDENTIFIES NOVEL RISK LOCI FOR GLIOMA.
22:ii71-ii72.
2020
-
Conversations on mutism: risk stratification for cerebellar mutism based on medulloblastoma subtype..
22:175-176.
2020
-
Highlights from the Literature.
22:13.
2020
-
SCIDOT-34. BRAIN INJURY SIGNALS SYSTEMIC IMMUNOSUPPRESSION THROUGH THYMIC INVOLUTION.
21:vi278-vi279.
2019
-
EXTH-36. BIFUNCTIONAL RNA NANOPARTICLES INDUCE ANTITUMOR IMMUNE RESPONSES AND ALLOW MRI-BASED DETECTION OF DENDRITIC CELL MIGRATION AS A BIOMARKER OF ANTITUMOR IMMUNE RESPONSE.
20:vi92-vi93.
2018
-
IMMU-24. THE IMPACT OF BRAIN TUMORS ON HEMATOPOIETIC STEM CELL-DERIVED T CELLS.
20:vi126-vi126.
2018
-
IMMU-32. RETARGETING IMMUNOEDITED GLIOMA ESCAPE VARIANTS WITH ADOPTIVE CELLULAR THERAPY.
20:vi128-vi128.
2018
-
TMIC-12. TUMOR-HOMING RNA-NANOPARTICLES REPROGRAM IMMUNE CELLS IN THE BRAIN TUMOR MICROENVIRONMENT.
20:vi258-vi258.
2018
-
TMIC-29. REPROGRAMMING BONE MARROW OF TUMOR-BEARING HOSTS FOR GLIOMA IMMUNOTHERAPY.
20:vi262-vi262.
2018
-
ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM).
20:vi4-vi4.
2018
-
EPID-13. ANTI-ANGIOGENIC THERAPY FOR HIGH-GRADE GLIOMA: A META-ANALYSIS.
20:vi82-vi83.
2018
-
RBTT-07. NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS.
20:vi235-vi235.
2018
-
P01.035 Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG): Trial in progress.
20:iii236-iii236.
2018
-
IMMU-17. HEMATOPOIETIC STEM CELL-DERIVED DENDRITIC CELLS REPROGRAM THE BRAIN TUMOR MICROENVIRONMENT.
20:i102-i102.
2018
-
IMMU-20. HEMATOPOIETIC STEM CELLS POTENTIATE EFFICACY OF ADOPTIVE CELL THERAPY AGAINST BRAIN STEM GLIOMA.
20:i102-i103.
2018
-
MBRS-63. CCR2+ HEMATOPOIETIC STEM CELLS OVERCOME TREATMENT RESISTANCE TO PD-1 IN MEDULLOBLASTOMA.
20:i141-i142.
2018
-
IMMU-30. TCR Vb CLONAL EXPANSION PREDICTS RESPONSE TO ADOPTIVE IMMUNOTHERAPY AGAINST MEDULLOBLASTOMA.
19:vi119-vi119.
2017
-
IMMU-65. Lin-CCR2+ HEMATOPOIETIC STEM CELLS OVERCOME RESISTANCE TO PD-1 BLOCKADE.
19:vi127-vi127.
2017
-
MNGI-14. LONG-TERM OUTCOMES FOLLOWING SURGERY AND/OR RADIATION THERAPY IN PATIENTS WITH HIGH-GRADE MENINGIOMA.
19:vi135-vi135.
2017
-
TMIC-12. REPROGRAMMING THE BRAIN TUMOR MICROENVIRONMENT WITH HEMATOPOIETIC STEM AND PROGENITOR CELLS.
19:vi245-vi245.
2017
-
Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma..
19:1469-1480.
2017
-
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer..
19:1481-1493.
2017
-
IMMU-22. ADOPTIVE CELL THERAPY AGAINST DIPG USING DEVELOPMENTALLY REGULATED ANTIGENS.
19:iv32-iv32.
2017
-
P01.20 Treatment of recurrent glioblastoma with the cytokine inhibitor, ibudilast in combination with temozolomide.
19:iii27-iii27.
2017
-
IMST-47. IDENTIFICATION AND EXPANSION OF GLIOMA-SPECIFIC T CELLS USING TCR Vβ EXPRESSION.
18:vi97-vi97.
2016
-
A PHASE I STUDY OF SINGLE-AGENT PERIFOSINE FOR RECURRENT/REFRACTORY PEDIATRIC CNS AND SOLID TUMORS.
18:25-25.
2016
-
ATPS-54GENOMICALLY UNSTABLE GLIOBLASTOMA (U-GBM) SHOW EXQUISITE SENSITIVITY TO PARP INHIBITION..
17:v30-v30.
2015
-
IMPS-07T CELL RECEPTOR VARIABLE β CHAIN (TCR Vβ) USAGE TO PREDICT AND GENERATE TUMOR SPECIFIC T LYMPHOCYTES AGAINST INVASIVE GLIOMAS.
17:v114.3-v114.
2015
-
IM-15 * ANTI-TUMOR EFFICACY OF ADOPTIVE CELLULAR THERAPY IS SIGNIFICANTLY INCREASED BY HEMATOPOIETIC STEM CELLS.
17:iii18-iii18.
2015
-
AT-19 * SINGLE INSTITUTION RETROSPECTIVE COMPARISON OF GLIOBLASTOMA (GBM) PATIENTS (PTS) INITIATED ON BEVACIZUMAB (BEV) BEFORE VERSUS AFTER RECURRENCE IN CLINICAL PRACTICE.
16:v12-v12.
2014
-
AT-20 * SINGLE INSTITUTION RETROSPECTIVE REVIEW OF PERFORMANCE STATUS AND CORTICOSTEROID USE IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS (PTS) TREATED ON BEVACIZUMAB (BEV).
16:v12-v13.
2014
-
AT-21 * FINAL RESULTS OF A PHASE 1 TRIAL OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA (GBM).
16:v13-v13.
2014
-
AT-22 * PHASE II TRIAL OF BEVACIZUMAB, RADIATION THERAPY (RT) AND TEMOZOLOMIDE FOLLOWED BY BEVACIZUMAB AND TEMOZOLOMIDE WITH CONTINUATION OF BEVACIZUMAB BEYOND PROGRESSION.
16:v13-v13.
2014
-
AT-48 * A PHASE 1 TRIAL OF CARBOXYAMIDOTRIAZOLE OROTATE (CTO) IN COMBINATION WITH BEVACIZUMAB FOR ADULT PATIENTS WITH RECURRENT MALIGNANT GLIOMA POST-BEVACIZUMAB FAILURE.
16:v19-v19.
2014
-
BM-17 * FINAL RESULTS OF A RANDOMIZED TRIAL TO IDENTIFY THE OPTIMAL PLANNING TARGET VOLUME IN IMAGE-GUIDED STEREOTACTIC RADIOSURGERY OF BRAIN METASTASES.
16:v35-v35.
2014
-
ET-28 * COMBINATION THERAPY WITH MET TYROSINE KINASE INHIBITOR EMD1214063 AND BEVACIZUMAB.
16:v85-v85.
2014
-
IT-10 * SYNERGISTIC CELLULAR INTERACTIONS IN ADOPTIVE IMMUNOTHERAPY LEADS TO IMMUNOLOGIC REJECTION OF MALIGNANT GLIOMA.
16:v111-v111.
2014
-
IT-28 * VACCINATION AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III IN GLIOBLASTOMA: THE RINDOPEPIMUT COMPASSIONATE USE EXPERIENCE.
16:v115-v116.
2014
-
IT-30 * ReACT: A PHASE II STUDY OF RINDOPEPIMUT VACCINE (CDX-110) PLUS BEVACIZUMAB IN RELAPSED GLIOBLASTOMA.
16:v116-v116.
2014
-
IT-34 * PILOT STUDY OF COMBINATION OF ANTITUMOR IMMUNOTHERAPY TARGETED AGAINST CYTOMEGALOVIRUS (CMV) PLUS REGULATORY T-CELL INHIBITION IN PATIENTS WITH NEWLY-DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM).
16:v117-v117.
2014
-
MS-19 * LONG-TERM OUTCOMES FOR PATIENTS WITH INTRACRANIAL MENINGIOMAS: A SINGLE-INSTITUTION RETROSPECTIVE ANALYSIS.
16:v130-v131.
2014
-
SM-02 * LEVETIRACETAM USAGE IN POST-OPERATIVE SEIZURE MANAGEMENT IN MALIGNANT GLIOMA.
16:v206-v206.
2014
-
LOW GRADE GLIOMAS..
16:i60-i70.
2014
-
Erratum.
16:760-760.
2014
-
ACTIVITY OF THE PAN-HER INHIBITOR PF-00299804 AGAINST A PANEL OF BRAIN TUMOR XENOGRAFTS.
13:164-164.
2011
-
DENDRITIC CELL VACCINES TARGETING CYTOMEGALOVIRUS IN GLIOBLASTOMA.
13:39-39.
2011
-
METABOLIC PATHWAYS.
13:iii69-iii72.
2011
-
METABOLOMICS PROFILING OF PATIENT CEREBROSPINAL FLUID IDENTIFIES SIGNATURES OF MALIGNANT GLIOMA.
13:69-69.
2011
-
MIBEFRADIL, A NOVEL THERAPY FOR GLIOBLATOMA MULTIFORME: INTERLACED THERAPY IN A MURINE MODEL.
13:108-109.
2011
-
PHASE II STUDY OF PANITUMUMAB IN COMBINATION WITH IRINOTECAN FOR MALIGNANT GLIOMA PATIENTS.
13:90-90.
2011
-
PRECLINICAL USE OF MILD HYPERTHERMIA TO ENHANCE DRUG DELIVERY TO BRAIN TUMORS.
13:111-111.
2011
-
PROGNOSTIC IMPORTANCE OF QUALITY OF LIFE AND FATIGUE IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMA.
13:123-123.
2011
-
THE ADDITION OF BEVACIZUMAB TO TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME.
13:89-90.
2011
-
TRUNCATED NEUROKININ 1 RECEPTOR: EXPRESSION IN PRIMARY GLIOBLASTOMAS AND RELATIONSHIP WITH PATIENT SURVIVAL.
13:82-82.
2011
-
REVERSIBLE OPENING OF THE BBB BY TARGETED SUPPRESSION OF CLAUDIN 5 TO ENHANCE DRUG DELIVERY TO BRAIN TUMORS.
12:98-98.
2010
-
In tribute to Mike Traynor (1939-2009).
11:724.
2009
-
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma..
11:556-561.
2009
-
Characterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma..
11:357-367.
2009
-
DUAL-SPECIFIC IMMUNOTOXIN, D2C7 (SCDSFV)-PE38KDEL, FOR BRAIN TUMOR TREATMENT.
11:223-223.
2009
-
EGF RECEPTOR TYROSINE KINASE MEDIATES A NOVEL PATHWAY OF DRUG RESISTANCE IN MALIGNANT GLIOMAS VIA TYROSINE PHOSPHORYLATION AND FUNCTIONAL ACTIVATION OF GLUTATHIONE S-TRANSFERASE P1.
11:218-218.
2009
-
INDUCTION OF IMMUNOLOGIC AND CLINICAL RESPONSES WITH EGFRVIII-TARGETED VACCINE (CDX-110) WITH CYCLES OF TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED EGFRVIII-POSITIVE GBM.
11:224-224.
2009
-
OTX2 IS ONCOGENIC AND PREDICTS DECREASED SURVIVAL IN MEDULLOBLASTOMA PATIENTS.
11:234-234.
2009
-
PHASE II STUDY OF BEVACIZUMAB AND ERLOTINIB IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME.
11:231-231.
2009
-
RECOMBINANT ANTIBODY-BASED MOLECULAR THERAPEUTICS FOR BRAIN TUMOR IMMUNOTHERAPY.
11:224-224.
2009
-
THE RNA-BINDING PROTEIN 76 CONTROLS GENE EXPRESSION IN GBM.
11:221-221.
2009
-
A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET..
11:33-40.
2009
-
Experience with irinotecan for the treatment of malignant glioma..
11:80-91.
2009
-
Abstracts for the Thirteenth Annual Meeting of the Society for Neuro-Oncology: November 20–23, 2008..
10:759-915.
2008
-
Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastoma..
10:745-751.
2008
-
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors..
10:320-329.
2008
-
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma..
10:330-340.
2008
-
A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost..
10:182-189.
2008
-
Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors..
10:171-181.
2008
-
Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study..
10:98-103.
2008
-
Multifocal anaplastic astrocytoma in a patient with hereditary colorectal cancer, transcobalamin II deficiency, agenesis of the corpus callosum, mental retardation, and inherited PMS2 mutation..
10:93-97.
2008
-
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma..
10:10-18.
2008
-
Prevalence of diabetes mellitus in adult patients with primary gliomas on steroid therapy.
9:567-568.
2007
-
Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice..
9:240-244.
2007
-
Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions..
9:343-353.
2007
-
Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report..
9:145-160.
2007
-
Temozolomide in children with progressive low-grade glioma..
9:161-168.
2007
-
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme..
9:70-74.
2007
-
Neuro-Oncology: Editorial.
8:289.
2006
-
GNOSIS: guidelines for neuro-oncology: standards for investigational studies-reporting of phase 1 and phase 2 clinical trials..
7:425-434.
2005
-
Neuro-Oncology impact factor for 2004.
7:423-424.
2005
-
Chaperone proteins and brain tumors: potential targets and possible therapeutics..
7:260-278.
2005
-
Mechanisms of action of rapamycin in gliomas..
7:1-11.
2005
-
Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study..
7:90-96.
2005
-
Editorial.
6:273.
2004
-
Poliovirus receptor CD155-targeted oncolysis of glioma..
6:208-217.
2004
-
Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer..
6:236-246.
2004
-
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma..
6:145-153.
2004
-
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma..
6:134-144.
2004
-
Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme..
6:38-43.
2004
-
Editorial.
5:227.
2003
-
Phase 2 study of idarubicin in pediatric brain tumors: Pediatric Oncology Group study POG 9237..
5:261-267.
2003
-
A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy..
4:261-267.
2002
-
Editorial.
4:241.
2002
-
Comprehensive molecular cytogenetic investigation of chromosomal abnormalities in human medulloblastoma cell lines and xenograft..
4:75-85.
2002
-
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience..
4:102-108.
2002
-
Carboplatin chemotherapy for progressive intramedullary spinal cord low-grade gliomas in children: three case studies and a review of the literature..
3:251-257.
2001
-
Ex vivo pediatric brain tumors express Fas (CD95) and FasL (CD95L) and are resistant to apoptosis induction..
3:229-240.
2001
-
Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas..
3:246-250.
2001
-
Carboplatin is effective therapy for young children with progressive optic pathway tumors: a Pediatric Oncology Group phase II study..
2:213-220.
2000
-
Comparative genetic patterns of glioblastoma multiforme: potential diagnostic tool for tumor classification..
2:164-173.
2000
-
High-dose methotrexate for primary CNS lymphoma in the elderly..
2:40-44.
2000
-
The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience..
1:152-161.
1999
-
Morphologic and molecular genetic aspects of oligodendroglial neoplasms..
1:52-60.
1999
-
The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif..
1:33-42.
1999
-
TMIC-15. AGE-RELATED MARKERS FOR SENESCENCE INCREASE IN THE OLDER ADULT EXTRATUMORAL MOUSE BRAIN DUE TO GLIOBLASTOMA
2022
-
P11.65.B GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple treatment regimens in newly diagnosed and recurrent glioblastoma
2022
-
A NOVEL, CLINICALLY-RELEVANT CLASSIFICATION OF PEDIATRIC CNS TUMORS FOR CANCER REGISTRIES USING A CLUSTERING ANALYSIS
2022
-
A PHASE II STUDY OF CONTINUOUS LOW DOSE PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH MALIGNANT RHABDOID TUMOURS AND ATYPICAL TERATOID RHABDOID TUMOURS
2022
-
A RETROSPECTIVE ANALYSIS OF THE IMPACT OF THE COVID-19 INFECTION ON NEURO-ONCOLOGY CARE AND PATIENT OUTCOMES: A TWO-SITE STUDY
2022
-
CHANGES IN SURVIVAL OVER TIME FOR ALL PRIMARY BRAIN AND OTHER CNS TUMORS IN THE UNITED STATES
2022
-
CHARACTERIZING THE LANDSCAPE OF STRUCTURAL VARIANTS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMA
2022
-
CLINICAL FEATURES AND MOLECULAR CHARACTERIZATION OF LEPTOMENINGEAL DISEASE IN PATIENTS WITH HIGH GRADE GLIOMA
2022
-
CXCR3 SIGNALING ENGAGES GLIOMA INFILTRATING T CELLS AND IS REQUIRED FOR THE ANTITUMOR EFFICACY OF INNATE STIMULATING IMMUNOTHERAPY
2022
-
DOSE ESCALATION TRIAL OF FC-ENGINEERED ANTI-CD40 MONOCLONAL ANTIBODY (2141-V11) ADMINISTERED INTRATUMORALLY WITH D2C7-IT VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMAS (RMGS)
2022
-
EFFICACY OF LASER INTERSTITIAL THERMAL THERAPY (LITT) FOR NEWLY DIAGNOSED AND RECURRENT IDH WILD-TYPE GLIOBLASTOMA
2022
-
ENHANCING T CELL TRAFFICKING OF CD3-ENGAGING IMMUNOTHERAPY TO TUMORS OF THE CENTRAL NERVOUS SYSTEM
2022
-
GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA
2022
-
IMPROVEMENTS IN SURVIVAL FOR GLIOBLASTOMA IN THE POST-STUPP PROTOCOL ERA
2022
-
MOLECULAR MARKER TESTING AND REPORTING COMPLETENESS FOR ADULT-TYPE DIFFUSE GLIOMAS IN THE UNITED STATES
2022
-
NATIONAL EPIDEMIOLOGY AND SURVIVAL OF ADULT-TYPE DIFFUSE GLIOMAS IN THE UNITED STATES BY IDH, 1P/19Q, MGMT, AND WHO CNS GRADE
2022
-
NUTMEG: A RANDOMIZED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE VERSUS TEMOZOLOMIDE ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS WITH GLIOBLASTOMA
2022
-
PHASE IB STUDY OF UNESBULIN (PTC596) IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) AND HIGH-GRADE GLIOMA (HGG): A REPORT FROM THE COLLABORATIVE NETWORK FOR NEURO-ONCOLOGY CLINICAL TRIALS (CONNECT)
2022
-
PHASE II RANDOMIZED STUDY TO EVALUATE EFFICACY AND SATISFACTION OF ROLAPITANT PLUS ONDANSETRON VS. ONDANSETRON MONOTHERAPY IN PREVENTING NAUSEA/VOMITING FOR GLIOMAS RECEIVING RADIATION/ TEMOZOLOMIDE
2022
-
RECONSTITUTION OF CGAS/STING PATHWAY VIA EPIGENETIC REPROGRAMMING LEADS TO ANTI-VIRAL INFLAMMATORY SIGNALING IN ATYPICAL TERATOID RHABDOID TUMORS (ATRTS)
2022
-
REPURPOSING CLEMASTINE TO SUPPRESS GLIOBLASTOMA STEM CELLS
2022
-
RESULTS OF A PHASE IB TRIAL OF RECOMBINANT POLIO:RHINOVIRUS IMMUNOTHERAPY FOR RECURRENT PEDIATRIC HIGH GRADE GLIOMA
2022
-
THE GENOMIC, TRANSCRIPTOMIC, AND EPIGENOMIC LANDSCAPE OF ISOCITRATE DEHYDROGENASE WILD TYPE GLIOBLASTOMA ACROSS THE AGE CONTINUUM
2022
-
THE LONGITUDINAL EVOLUTIONARY TRAJECTORY OF OLIGODENDROGLIOMA IS DRIVEN BY TREATMENT-ASSOCIATED GENETIC ALTERATIONS
2022
-
THE ROLE OF SMARCAL1 AS A SYNTHETIC LETHAL VULNERABILITY IN ATRX-DEFICIENT GLIOMAS
2022
-
UPDATE ON GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA.
2022
-
BIOM-17. DIFFERENCES IN THE IMMUNE MICROENVIRONMENT OF GLIOMAS HARBORING IDH2 VERSUS IDH1 MUTATIONS
2021
-
CTIM-10. REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA
2021
-
CTIM-18. LUMINOS-101: INITIAL SAFETY AND TOLERABILITY OF PVSRIPO AND PEMBROLIZUMAB COMBINATION THERAPY IN RECURRENT GLIOBLASTOMA
2021
-
EPID-06. ASSOCIATIONS BETWEEN GERMLINE GENETIC VARIANTS AND OVERALL SURVIVAL IN PATIENTS WITH GLIOMA
2021
-
EPID-09. VARIATION IN GLIOMA INCIDENCE AMONG US HISPANICS BY GEOGRAPHIC REGION OF ORIGIN
2021
-
EPID-11. A POPULATION STUDY OF CLINICAL TRIAL ACCRUAL FOR WOMEN AND MINORITIES IN NEURO-ONCOLOGY FOLLOWING THE NIH REVITALIZATION ACT
2021
-
EPID-26. ALIGNING THE CBTRUS HISTOLOGY GROUPS WITH 2016 WHO CLASSIFICATION OF TUMORS OF THE CENTRAL NERVOUS SYSTEM
2021
-
EXTH-59. GENERATION OF A THIRD GENERATION CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOBLASTOMA
2021
-
IMMU-26. SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS
2021
-
INNV-20. RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB
2021
-
INNV-31. NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE
2021
-
QOLP-10. A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS
2021
-
QOLP-28. COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE U.S. SAMPLE
2021
-
BIOL-10. DISTRIBUTION AND VULNERABILITY OF TRANSCRIPTIONAL OUTPUTS ACROSS THE GENOME IN MYC-AMPLIFIED MEDULLOBLASTOMA CELLS
2021
-
EPCT-01. A NOVEL PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL
2021
-
LGG-08. TREATMENT OUTCOMES AND TOLERABILITY OF TRAMETINIB IN PROGRESSIVE CIRCUMSCRIBED LOW-GRADE GLIOMAS
2021
-
A LONGITUDINAL OBSERVATIONAL STUDY OF EXERCISE BEHAVIOR IN GLIOBLASTOMA PATIENTS TREATED WITH TUMOR-TREATING FIELDS
2021
-
ALIGNING THE CBTRUS HISTOLOGY GROUPS WITH 2016 WHO CLASSIFICATION OF TUMORS OF THE CENTRAL NERVOUS SYSTEM
2021
-
ASSOCIATIONS BETWEEN GERMLINE GENETIC VARIANTS AND OVERALL SURVIVAL IN PATIENTS WITH GLIOMA
2021
-
CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH DESMOPLASTIC/EXTENSIVE NODULAR MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING - A COMPARATIVE OUTCOMES ANALYSIS OF PROSPECTIVE MULTI-CENTER EUROPEAN AND NORTH AMERICAN TRIALS
2021
-
COMPARING KNOWLEDGE OF AND BELIEFS ABOUT PALLIATIVE CARE AMONG NEURO-ONCOLOGY PATIENTS, CAREGIVERS, PROVIDERS AND A NATIONALLY-REPRESENTATIVE US SAMPLE
2021
-
CONJOINED CLASS I AND II EPITOPES ENHANCE NEOANTIGEN-TARGETED ACTIVE IMMUNOTHERAPY
2021
-
DIFFERENCES IN THE IMMUNE MICROENVIRONMENT OF GLIOMAS HARBORING IDH2 VERSUS IDH1 MUTATIONS
2021
-
EFFICACY OF SOLUBLE PANOBINOSTAT (MTX110) IN PRECLINICAL MODELS OF ADULT GLIOBLASTOMA
2021
-
GENERATION OF A THIRD GENERATION CAR T CELL THAT SIMULTANEOUSLY TARGETS WILDTYPE EGFR AND ITS MUTANT ISOFORM EGFRVIII FOR TREATMENT OF GLIOBLASTOMA
2021
-
IL-12 ARMORED CAR T CELL THERAPY FOR HETEROGENEOUS GLIOBLASTOMA
2021
-
IMPORTANCE OF THE INTERSECTION OF AGE AND SEX TO UNDERSTAND VARIATION IN INCIDENCE AND SURVIVAL FOR PRIMARY MALIGNANT GLIOMAS
2021
-
LONGITUDINAL ANALYSIS OF DIFFUSE GLIOMA REVEALS CELL STATE DYNAMICS AT RECURRENCE ASSOCIATED WITH CHANGES IN GENETICS AND THE MICROENVIRONMENT
2021
-
LOW AND INTERMEDIATE GRADE GLIOMA UMBRELLA STUDY OF MOLECULAR GUIDED THERAPIES (LUMOS) STUDY
2021
-
NEURO-ONCOLOGY OUTPATIENT SATISFACTION IS MAINTAINED IN THE ERA OF COVID-19 TELEMEDICINE
2021
-
POLIO VIROTHERAPY OF MURINE BRAIN TUMORS INDUCES MICROGLIA PROLIFERATION AND INFLAMMATION THAT IS POTENTIATED BY IMMUNE CHECKPOINT BLOCKADE
2021
-
RADIOGRAPHIC RESPONSE AND SEIZURE CONTROL IN IDH1 MUTANT GLIOMA PATIENTS USING IVOSIDENIB
2021
-
REPRODUCIBILITY OF CLINICAL TRIALS USING CMV-TARGETED DENDRITIC CELL VACCINES IN PATIENTS WITH GLIOBLASTOMA
2021
-
SAFETY AND EFFICACY OF PVSRIPO IN RECURRENT GLIOBLASTOMA: LONG-TERM FOLLOW-UP AND INITIAL MULTICENTER RESULTS
2021
-
STING IS SILENCED IN GBM BY PROMOTER METHYLATION THAT IS ESTABLISHED BY TISSUE OF ORIGIN
2021
-
T CELL HITCHHIKING AS A MECHANISM OF DRUG DELIVERY TO THE BRAIN
2021
-
TUMOR-INTRINSIC AND PERIPHERAL FEATURES ASSOCIATE WITH SURVIVAL AFTER POLIO VIROTHERAPY IN RECURRENT GBM
2021
-
VARIATION IN GLIOMA INCIDENCE AMONG US HISPANICS BY GEOGRAPHIC REGION OF ORIGIN
2021
-
EPCT-13. CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: PHASE I TRIAL RESULTS
2020
-
EPID-16. INTEGRATION OF EHR AND CANCER REGISTRY DATA TO CONSTRUCT A PEDIATRIC NEURO-ONCOLOGY SURVIVORSHIP COHORT AND IMPROVE LONG-TERM FOLLOW-UP CARE
2020
-
MBCL-25. PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES
2020
-
THER-05. GENETICALLY STABLE POLIOVIRUS VECTOR CARRYING H3.3K27M ANTIGEN FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA BY INTRAMUSCULAR INJECTION
2020
-
BIOM-17. BRAF MUTATION IS AN EARLY EVENT IN THE EVOLUTION OF A SUBSET OF GLIOBLASTOMAS AND IS ASSOCIATED WITH INCREASED PD-L1 EXPRESSION
2020
-
CTIM-21. PEPTIDE VACCINE DIRECTED TO CMV pp65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL
2020
-
CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG)
2020
-
DDRE-20. GENERATION OF A HIGH-AFFINITY EGFR/EGFRvIII-TARGETED D2C7 CAR-T CELL
2020
-
QOLP-20. A FEASIBILITY STUDY UTILIZING MINDFULNESS MEDITATION DURING CONCOMITANT CHEMORADIATION IN MALIGNANT GLIOMA PATIENTS: HEALTH-REPORTED QUALITY OF LIFE (HRQOL) RESULTS
2020
-
A FEASIBILITY STUDY UTILIZING MINDFULNESS MEDITATION DURING CONCOMITANT CHEMORADIATION IN MALIGNANT GLIOMA PATIENTS: HEALTH-REPORTED QUALITY OF LIFE (HRQOL) RESULTS
2020
-
A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG)
2020
-
A PHASE II STUDY OF CONTINUOUS LOW DOSE PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH MALIGNANT RHABDOID TUMORS/ATYPICAL TERATOID RHABDOID TUMORS
2020
-
A PILOT CLINICAL TRIAL OF OROTECAN (VAL-413), A NOVEL ORAL DOSAGE FORMULATION OF IRINOTECAN: IMPLICATIONS FOR PEDIATRIC BRAIN TUMORS
2020
-
ANALYSIS OF IMMUNE SIGNATURES IN PEDIATRIC GLIOBLASTOMAS FOR PATIENT STRATIFICATION TO IMMUNOTHERAPY
2020
-
BRAF MUTATION IS AN EARLY EVENT IN THE EVOLUTION OF A SUBSET OF GLIOBLASTOMAS AND IS ASSOCIATED WITH INCREASED PD-L1 EXPRESSION
2020
-
CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH CLASSIC (CLMB) OR ANAPLASTIC/LARGE CELL (A/LCMB) MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING - A COMPARATIVE OUTCOMES ANALYSIS
2020
-
CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH DESMOPLASTIC/EXTENSIVE NODULAR MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING - A COMPARATIVE OUTCOMES ANALYSIS OF PROSPECTIVE MULTI-CENTER EUROPEAN AND NORTH AMERICAN TRIALS
2020
-
CLINICAL CHARACTERISTICS OF LOW GRADE GLIOMA PATIENTS WITH NON-CANONICAL IDH1 AND IDH2 MUTATIONS
2020
-
CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: PHASE I TRIAL RESULTS
2020
-
COMBINATION LASER INTERSTITIAL THERMAL THERAPY PLUS SRS INCREASES TIME TO PROGRESSION FOR RECURRENT SRS-TREATED BRAIN METASTASES
2020
-
CYTOSTATIC HYPOTHERMIA FOR GLIOBLASTOMA
2020
-
EFFICACY OF SOLUBLE PANOBINOSTAT (MTX110) IN PRECLINICAL MODELS OF ADULT GLIOBLASTOMA
2020
-
ENGAGING PATIENTS AND CAREGIVERS TO IMPROVE THE IMPORTANCE AND QUALITY OF SUPPORTIVE CARE RESEARCH IN NEURO-ONCOLOGY
2020
-
EPIGENETIC REPROGRAMMING LEADS TO INNATE IMMUNE PATHWAY ACTIVATION IN AT/RT
2020
-
FACTORS ASSOCIATED WITH LONGER SURVIVAL AFTER FIRST RECURRENCE IN MEDULLOBLASTOMA BY MOLECULAR SUBGROUP AFTER RISK-BASED INITIAL THERAPY
2020
-
GBM AGILE: A GLOBAL, PHASE 2/3 ADAPTIVE PLATFORM TRIAL TO EVALUATE MULTIPLE REGIMENS IN NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
2020
-
GENERATION OF A HIGH-AFFINITY EGFR/EGFRVIII-TARGETED D2C7 CAR-T CELL
2020
-
GENETIC PREDISPOSITION TO LONGER TELOMERE LENGTH AND RISK OF CHILDHOOD, ADOLESCENT AND ADULT-ONSET EPENDYMOMA
2020
-
GENETICALLY STABLE POLIOVIRUS VECTOR CARRYING H3.3K27M ANTIGEN FOR TREATMENT OF DIFFUSE MIDLINE GLIOMA BY INTRAMUSCULAR INJECTION
2020
-
GLIOBLASTOMA IN THE OLDER PERSON - HOW DO WE DECIDE ON TREATMENT?
2020
-
INTEGRATION OF EHR AND CANCER REGISTRY DATA TO CONSTRUCT A PEDIATRIC NEURO-ONCOLOGY SURVIVORSHIP COHORT AND IMPROVE LONG-TERM FOLLOW-UP CARE
2020
-
INTERPLAY BETWEEN IDH1 AND ATRX MUTATIONS GOVERN INNATE IMMUNE RESPONSES IN GLIOMAS
2020
-
MODELING UPFRONT GLIOBLASTOMA SURGICAL RESECTION AND STEROID USE REVEALS IMMUNOSUPPRESSIVE CHANGES AND SUGGESTS THAT PERIPHERAL LYMPHOCYTE COUNTS ARE ASSOCIATED WITH TUMOR VOLUME AND PROGNOSIS
2020
-
OLANZAPINE FOR REFRACTORY CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS
2020
-
ONCOLYTIC POLIOVIRUS AS A PROBE FOR MECHANISMS OF IMMUNE RESISTANCE IN GLIOBLASTOMA
2020
-
PATTERNS OF DISTRESS IN OLDER PATIENTS WITH GLIOBLASTOMA: A FOLLOW-UP TO A SINGLE INSTITUTION CROSS-SECTIONAL STUDY OF DISTRESS IN PRIMARY BRAIN TUMOR PATIENTS
2020
-
PEPTIDE VACCINE DIRECTED TO CMV PP65 FOR TREATMENT OF RECURRENT MALIGNANT GLIOMA AND MEDULLOBLASTOMA IN CHILDREN AND YOUNG ADULTS: PRELIMINARY RESULTS OF A PHASE I TRIAL
2020
-
PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA: UPDATED OUTCOMES
2020
-
QUANTIFYING THE POTENTIAL PUBLIC HEALTH IMPACT OF VARICELLA ZOSTER VIRUS (VZV) VACCINATION ON GLIOMA INCIDENCE
2020
-
RADIOGRAPHIC CHARACTERISTICS AND STEROID USAGE IN LASER INTERSTITIAL THERMAL THERAPY VERSUS MEDICAL MANAGEMENT FOR BIOPSY-PROVEN RADIATION NECROSIS AFTER STEREOTACTIC RADIOSURGERY OF BRAIN METASTASES
2020
-
STING PROMOTER EPIGENETIC SILENCING IN GLIOBLASTOMA
2020
-
THE PARADOXICAL EFFECTS OF COVID-19 ON CANCER CARE IN THE NEURO-ONCOLOGY SETTING
2020
-
ATIM-24. DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG)
2019
-
CHARACTERISTICS OF SHORT-TERM SURVIVAL IN PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE ANALYSIS
2019
-
DOSE FINDING AND DOSE EXPANSION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG)
2019
-
HOUT-21. CHARACTERISTICS OF SHORT-TERM SURVIVAL IN PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE ANALYSIS
2019
-
MINDFULNESS MEDITATION PRACTICE IN MALIGNANT GLIOMA PATIENTS THROUGHOUT CONCOMITANT RADIATION AND TEMOZOLOMIDE: A FEASIBILITY STUDY
2019
-
PDCT-10. FEASIBILITY OF LEUKAPHERESIS FOR HARVESTING MONOCYTES AND GENERATING AUTOLOGOUS DENDRITIC CELL VACCINES IN CHILDREN WITH MALIGNANT BRAIN TUMORS
2019
-
QOLP-29. MINDFULNESS MEDITATION PRACTICE IN MALIGNANT GLIOMA PATIENTS THROUGHOUT CONCOMITANT RADIATION AND TEMOZOLOMIDE: A FEASIBILITY STUDY
2019
-
QOLP-34. DOSE FREQUENCY MODIFICATION OF TRAMETINIB TO MITIGATE SEVERE RASH AND IMPROVE QUALITY OF LIFE IN PEDIATRIC LOW-GRADE GLIOMA PATIENTS
2019
-
SAFETY OF TUMOR-SPECIFIC PEPTIDE VACCINE TARGETING ISOCITRATE DEHYDROGENASE 1 MUTATION IN RECURRENT RESECTABLE LOW GRADE GLIOMA PATIENTS
2019
-
A RANDOMIZED PHASE 2 TRIAL OF CEDIRANIB IN COMBINATION WITH OLAPARIB VERSUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA
2019
-
A SERIES OF PATIENTS (PTS) WITH RECURRENT GBM (rGBM) TREATED WITH ABT-414, BEVACIZUMAB (BEV) AND CCNU
2019
-
A TIME-BASED MODEL OF EARLY PALLIATIVE CARE INTERVENTION IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA, A SINGLE INSTITUTION FEASIBILITY STUDY
2019
-
AMG 596, A NOVEL ANTI-EGFRVIII BISPECIFIC T CELL ENGAGER (BITE (R)) MOLECULE FOR THE TREATMENT OF GLIOBLASTOMA (GBM): PLANNED INTERIM ANALYSIS IN RECURRENT GBM (RGBM)
2019
-
ATRX MUTATIONS PREDICT RESPONSE TO INNATE BASED THERAPY IN GLIOMA
2019
-
CHEMOTHERAPY STRATEGIES FOR YOUNG CHILDREN NEWLY DIAGNOSED WITH MEDULLOBLASTOMA UP TO THE ERA OF MOLECULAR PROFILING - A COMPARATIVE OUTCOMES ANALYSIS
2019
-
DOSE FREQUENCY MODIFICATION OF TRAMETINIB TO MITIGATE SEVERE RASH AND IMPROVE QUALITY OF LIFE IN PEDIATRIC LOW-GRADE GLIOMA PATIENTS
2019
-
ENHANCED DRUG DELIVERY AND CIRCULATION WITH THE NEURAPHERESIST SYSTEM FOR THE TREATMENT OF LEPTOMENINGEAL METASTASES
2019
-
FEASIBILITY OF LEUKAPHERESIS FOR HARVESTING MONOCYTES AND GENERATING AUTOLOGOUS DENDRITIC CELL VACCINES IN CHILDREN WITH MALIGNANT BRAIN TUMORS
2019
-
FIRST-IN-HUMAN DOSING CONSIDERATIONS OF A BISPECIFIC ANTIBODY FOR TREATING GLIOBLASTOMA
2019
-
GENETICALLY STABLE POLIOVIRUS VECTOR PLATFORM FOR DIPG IMMUNOTHERAPY
2019
-
HEALTHCARE RESOURCE UTILIZATION OF LEPTOMENINGEAL CARCINOMATOSIS IN THE UNITED STATES
2019
-
LDSCORE REGRESSION IDENTIFIES NOVEL ASSOCIATIONS BETWEEN GLIOMA AND AUTO-IMMUNE CONDITIONS
2019
-
MOLECULAR AND CLONAL EVOLUTION IN RECURRENT METASTATIC GLIOSARCOMA
2019
-
PURSUIT OF AN INTERNATIONAL LANGUAGE OF GLIOMA RESEARCH: COMMON DATA ELEMENTS FOR THE LONGITUDINAL STUDY OF ADULT MALIGNANT GLIOMA
2019
-
SHARED GENOMIC ARCHITECTURE OF GLIOMA AND NEURO-COGNITIVE AND NEURO-PSYCHIATRIC TRAITS REVEALED BY LD-SCORE REGRESSION
2019
-
TUMOR MUTATIONAL BURDEN PREDICTS RESPONSE TO ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF TRANSCRIPTIONAL AND IMMUNOLOGICAL CORRELATES
2019
-
PL3.1 A phase 1, open-label, perioperative study of ivosidenib (AG-120) and vorasidenib (AG-881) in recurrent, IDH1-mutant, low-grade glioma: results from cohort 1
2019
-
LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY, PBTC-029B
2019
-
PILOT STUDY OF A SURGERY AND CHEMOTHERAPY-ONLY APPROACH IN THE UPFRONT THERAPY OF CHILDREN WITH WNT-POSITIVE STANDARD RISK MEDULLOBLASTOMA
2019
-
ACTR-28. PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS
2018
-
CLINICAL AND HISTOPATHOLOGICAL CHARACTERISTICS OF YOUNG ADULTS WITH GLIOBLASTOMA AT DIAGNOSIS
2018
-
DOSE ESCALATION TRIAL OF D2C7 IMMUNOTOXIN (D2C7-IT) ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG)
2018
-
EXTH-79. BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS
2018
-
PHASE 1 DOSE ESCALATION TRIAL OF THE SAFETY OF BMX-001 CONCURRENT WITH RADIATION THERAPY AND TEMOZOLOMIDE IN NEWLY DIAGNOSED PATIENTS WITH HIGH-GRADE GLIOMAS
2018
-
PSYCHOSOCIAL DISTRESS IN PATIENTS WITH RECURRENT MENINGIOMAS
2018
-
TREATMENT PATTERNS, OUTCOMES, AND PROGNOSTIC INDICATORS IN ELDERLY PATIENTS WITH GLIOBLASTOMA: A RETROSPECTIVE SINGLE INSTITUTION ANALYSIS
2018
-
A NOVEL NANOTECHNOLOGY-BASED PLATFORM IMPROVES LASER INTERSTITIAL THERMAL THERAPY FOR INTRACRANIAL TUMORS
2018
-
ANTI-ANGIOGENIC THERAPY FOR HIGH-GRADE GLIOMA: A META-ANALYSIS
2018
-
BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE, TYROSINE KINASE INHIBITION, AND MEK INHIBITION ARE EFFECTIVE AGAINST PLEOMORPHIC XANTHOASTROCYTOMA REGARDLESS OF V600E STATUS
2018
-
DYSFUNCTIONAL STING PATHWAY SIGNALING COMPROMISES INNATE IMMUNITY IN GLIOBLASTOMA
2018
-
ENHANCING VACCINE RESPONSES WITH DOSE-INTENSIFIED TEMOZOLOMIDE IN GLIOBLASTOMA: INITIATION OF THE I-ATTAC TRIAL
2018
-
ESTABLISHMENT AND PRELIMINARY EVALUATION OF BEVACIZUMAB-RESISTANT GLIOMA XENOGRAFT MODELS
2018
-
INTRATUMORAL ADMINISTRATION OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) IN MALIGNANT GLIOMA PATIENTS: ASSESSMENT OF MUTATIONAL RESPONSE CORRELATES
2018
-
LASER ABLATION FOR BRAIN METASTASES: SAFETY AND PRELIMINARY OUTCOMES FROM THE LASER ABLATION OF ABNORMAL NEUROLOGICAL TISSUE USING ROBOTIC NEUROBLATE SYSTEM (LAANTERN) REGISTRY
2018
-
MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM
2018
-
NUTMEG: A RANDOMISED PHASE II STUDY OF NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM): TRIAL IN PROGRESS
2018
-
PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM)
2018
-
POLIOVIRUS RECEPTOR (CD155) EXPRESSION IN PEDIATRIC BRAIN TUMORS MEDIATES ONCOLYSIS OF MEDULLOBLASTOMA AND PLEOMORPHIC XANTHOASTROCYTOMA
2018
-
PREVENTING T-CELL S1P1 INTERNALIZATION OBVIATES BONE MARROW T CELL SEQUESTRATION AND IMPROVES IMMUNOTHERAPEUTIC EFFICACY IN GBM
2018
-
REVIEW AND META-ANALYSIS OF NAUSEA AND VOMITING TRIALS FOR MALIGNANT GLIOMAS
2018
-
THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA
2018
-
THE GENOMIC LANDSCAPE OF TRIPLE-NEGATIVE GLIOBLASTOMA
2018
-
UPFRONT MRI-GUIDED STEREOTACTIC LASER-ABLATION IN NEWLY DIAGNOSED GLIOBLASTOMA: A MULTICENTER REVIEW OF SURVIVAL OUTCOMES COMPARED TO A MATCHED COHORT OF BIOPSY-ONLY PATIENTS
2018
-
NIVOLUMAB AND TEMOZOLOMIDE (TMZ) VS TMZ ALONE IN NEWLY DIAGNOSED ELDERLY PATIENTS (PTS) WITH GLIOBLASTOMA (GBM) (NUTMEG): TRIAL IN PROGRESS
2018
-
HGG-22. PHASE 1b STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN
2018
-
IMMU-21. TARGETING EGFR IN HYPOMUTATED PEDIATRIC BRAIN TUMORS USING THE D2C7 IMMUNOTOXIN
2018
-
IMMU-23. CMV pp65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: A PHASE I TRIAL
2018
-
A PHASE II STUDY OF PANOBINOSTAT IN PAEDIATRIC PATIENTS WITH SOLID TUMORS INCLUDING MALIGNANT RHABDOID TUMOR/ATYPICAL TERATOID RHABDOID TUMOURS
2018
-
CMV PP65 RNA-PULSED DENDRITIC CELL VACCINES FOR PEDIATRIC GLIOBLASTOMA AND MEDULLOBLASTOMA: A PHASE I TRIAL
2018
-
EVALUATION OF COBIMETINIB, A MEK INHIBITOR, IN LOW-GRADE PEDIATRIC BRAIN TUMORS
2018
-
PHASE 1B STUDY POLIO VACCINE SABIN-RHINOVIRUS POLIOVIRUS (PVSRIPO) FOR RECURRENT MALIGNANT GLIOMA IN CHILDREN
2018
-
RE-MATCH PROTOCOL: PHASE I STUDY OF AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (ALT) plus DC VACCINE (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND AUTOLOGOUS STEM CELL RESCUE (HDC plus ASCR) OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) IN PATIENTS WITH RECURRENT CENTRAL PNETS (R-PNET)
2018
-
TARGETING EGFR IN HYPOMUTATED PEDIATRIC BRAIN TUMORS USING THE D2C7 IMMUNOTOXIN
2018
-
RARE-25. A RETROSPECTIVE, SINGLE INSTITUTION STUDY OF CENTRAL NEUROCYTOMA (2004-2016): SURVIVAL, TREATMENT, AND SUPPORTIVE CARE
2017
-
A SINGLE INSTITUTION'S EXPERIENCE EXPLORING THE ASSOCIATION OF INTEGRATIVE MEDICINE AND SURVIVORSHIP IN GLIOBLASTOMA
2017
-
ANTITUMOR EFFICACY OF ANTI-PDL1 IN ACTH-SECRETING PITUITARY ADENOMAS: AN IMMUNOTHERAPEUTIC APPROACH FOR CUSHING'S DISEASE
2017
-
BIOMARKER ANALYSIS SUPPORTS THE VB-111 DUAL MECHANISM OF ACTION
2017
-
ENHANCED IN VIVO EFFICACY AND SAFETY OF COMBINATION TEMOZOLOMIDE AND BROMODOMAIN INHIBITOR THERAPY FOR GLIOMAS USING A TARGETED DUAL DRUG-LOADING STEALTH LIPOSOMAL CARRIER
2017
-
HETEROGENEITY OF EGFRvIII-POSITIVE GLIOBLASTOMA STEM CELLS: IMPLICATIONS FOR PERSONALIZED DRUG DEVELOPMENT
2017
-
INCREASED FATIGUE ASSOCIATED WITH TUMOR PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS
2017
-
LONG-TERM OUTCOMES FOLLOWING SURGERY AND/OR RADIATION THERAPY IN PATIENTS WITH HIGH-GRADE MENINGIOMA
2017
-
MAINTENANCE OF HEALTH RELATED QUALITY OF LIFE (QOL) BEYOND PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS TREATED WITH BEVACIZUMAB
2017
-
PAN-CANCER PROFILES OF BRAIN METASTASES: PRIORITIZATION OF THERAPEUTIC TARGETS
2017
-
PATTERNS OF RELAPSE AFTER SUCCESSFUL COMPLETION OF INITIAL THERAPY IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
2017
-
PERAMPANEL FOR TREATMENT OF REFRACTORY SEIZURES IN PATIENTS WITH GLIOMAS
2017
-
PHASE 2 STUDY OF SYM004 FOR ADULT PATIENTS WITH RECURRENT GLIOBLASTOMA (GBM)
2017
-
SYSTEMIC AND CONVECTION-ENHANCED DELIVERY OF DASATINIB EXTENDS SURVIVAL IN MURINE HISTONE H3.3K27M MUTANT BRAINSTEM GLIOMA
2017
-
TARGETED CATALYTIC INHIBITION OF EZH2 SYNERGIZES WITH LOW-DOSE PANOBINOSTAT IN MALIGNANT RHABDOID TUMOR
2017
-
A PHASE II PROSPECTIVE STUDY OF SELUMETINIB IN CHILDREN WITH RECURRENT OR REFRACTORY LOW-GRADE GLIOMA (LGG): A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY
2017
-
IMPACT OF STROKE AND STROKE RECURRENCE ON LATE MORTALITY AS WELL AS PSYCHOLOGICAL AND SOCIOECONOMIC OUTCOMES IN CHILDHOOD CANCER SURVIVORS
2017
-
TARGETED CATALYTIC INHIBITION OF EZH2 SYNERGIZES WITH LOW-DOSE PANOBINOSTAT IN MALIGNANT RHABDOID TUMOR
2017
-
TREATMENT OF RECURRENT GLIOBLASTOMA WITH THE CYTOKINE INHIBITOR, IBUDILAST IN COMBINATION WITH TEMOZOLOMIDE
2017
-
A COMBINATION OF PALBOCICLIB AND RADIOTHERAPY IMPROVES SURVIVAL IN GLIOBLASTOMA
2016
-
A CROSS-SECTIONAL STUDY OF DISTRESS THROUGHOUT THE DISEASE TRAJECTORY IN PRIMARY BRAIN TUMOR PATIENTS
2016
-
A FULLY-HUMAN EGFRvIII-TARGETED BISPECIFIC ANTIBODY REDIRECTS HUMAN T CELLS TO SPECIFICALLY LYSE MALIGNANT GLIOMA
2016
-
CAR T CELLS INDUCE COMPLETE REGRESSION OF MURINE GLIOBLASTOMA AFTER PRECONDITIONING HOSTS WITH TEMOZOLOMIDE
2016
-
DEMOGRAPHICS AND LIFESTYLE FACTORS IN GLIOMA RISK: A REPORT FROM THE GLIOMA INTERNATIONAL CASE-CONTROL STUDY
2016
-
DEVELOPMENT OF A PEPTIDE VACCINE PLATFORM FOR BRAIN TUMOR IMMUNOTHERAPY THAT INCORPORATES ADJUVANT CD27 STIMULATION FOR ENHANCED T CELL IMMUNITY
2016
-
DOWNREGULATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR TYPE 1 MEDIATES BONE MARROW T-CELL SEQUESTRATION IN PATIENTS AND MICE WITH GLIOBLASTOMA
2016
-
EXPRESSION OF PDL-1 ON PITUITARY ADENOMAS: A ROLE FOR IMMUNOTHERAPY
2016
-
IMMUNE CHECKPOINT BLOCKADE AS A POTENTIAL THERAPEUTIC TARGET: SURVEYING CNS MALIGNANCIES
2016
-
LYMPHOPENIA ENHANCES THE EFFICACY OF CAR T CELLS DELIVERED LOCO-REGIONALLY IN THE BRAIN FOR THE TREATMENT OF GLIOBLASTOMA
2016
-
NEUROCOGNITION IN LOW-GRADE GLIOMAS: ASSOCIATIONS WITH MEASURABLE AND PERCEIVED IMPAIRMENTS
2016
-
OUTCOMES OF SECOND SURGERY FOR RECURRENT GLIOBLASTOMA MULTIFORME: A RETROSPECTIVE CASE CONTROL STUDY
2016
-
PHASE I DOSE ESCALATION STUDY OF D2C7-IT ADMINISTERED INTRATUMORALLY VIA CONVECTION-ENHANCED DELIVERY (CED) FOR RECURRENT MALIGNANT GLIOMA (MG)
2016
-
REPURPOSING IBUDILAST IN COMBINATION WITH TEMOZOLOMIDE FOR GLIOBLASTOMA
2016
-
SCREENING BIOMARKERS IN GLIAL TUMORS TO IDENTIFY PREDICTORS OF SEIZURE ACTIVITY: A PROOF OF CONCEPT USING ISOCITRATE DEHYDROGENASE 1 (IDH-1) MUTATION STATUS
2016
-
T CELL EXHAUSTION IN PATIENTS AND MICE WITH GBM
2016
-
PALB2 (PARTNER AND LOCALIZER OF BRCA2) HETEROZYGOUS GERMLINE MUTATION IN A CHILD WITH EXTRA OSSEOUS EWING'S SARCOMA (EOEWS) OF BRAIN AND RADIATION-INDUCED METASTATIC MELANOMA (MM)
2016
-
IMPROVED SURVIVAL AND PROGNOSTIC ABILITY IN LUNG CANCER PATIENTS WITH BRAIN METASTASES: AN UPDATE OF THE GRADED PROGNOSTIC ASSESSMENT FOR LUNG CANCER USING MOLECULAR MARKERS (LUNG-molGPA)
2016
-
INHIBITION OF EPIGENETIC REGULATION AS A THERAPY FOR PEDIATRIC HIGH GRADE GLIOMA
2015
-
AT-46 VORINOSTAT AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMA: INTERIM ANALYSIS OF A PHASE II CLINICAL TRIAL
2014
-
CS-06 * EGFR PHOSPHORYLATION OF DCBLD2 RECRUITS TRAF6 AND STIMULATES Akt-PROMOTED TUMORIGENESIS
2014
-
QL-20 PROGNOSTIC IMPORTANCE OF HEALTH-RELATED QUALITY OF LIFE AND FATIGUE IN NEWLY DIAGNOSED GLIOBLASTOMA
2014
-
QL-21 SPIRITUAL WELL-BEING AND ITS ASSOCIATION WITH HEALTH-RELATED QUALITY OF LIFE IN PRIMARY BRAIN TUMOR PATIENTS
2014
-
EGFR PHOSPHORYLATION OF DCBLD2 RECRUITS TRAF6 AND STIMULATES AKT-PROMOTED TUMORIGENESIS
2014
-
NEXT-GENERATION RECOMBINANT IMMUNOTOXINS FOR GLIOBLASTOMAS AND MELANOMAS TREATMENT
2014
-
HER2 AMPLIFICATION OR POLYSOMY CHROMOSOME 17 (PCH17) IN BRAINSTEM PILOCYTIC ASTROCYTOMA (PA)
2014
-
LOW DOSE HISTONE DEACETYLASE INHIBITOR TREATMENT HALTS RHABDOID TUMOUR GROWTH AND INDUCES OSTEOGENESIS AND NEURONAL DIFFERENTIATION
2014
-
METASTATIC GLIOFIBROMA (GF) IN AN INFANT WITH BRAF: KIAA1549 GENE REARRANGEMENT AND RESPONSE TO WEEKLY VINBLASTINE (VBL) CHEMOTHERAPY
2014
-
PRE-CLINICAL EFFICACY STUDY OF INTRA-THECAL (IT) (LU)-L-177-DOTA-TATE (SOMATOSTATIN ANALOGUE) IN ATHYMIC RATS WITH LEPTOMENINGEAL DISEASE (LMD) FROM MEDULLOBLASTOMA (MBL)
2014
-
A BISPECIFIC ANTIBODY REDIRECTS REGULATORY T CELLS TO KILL TUMOR CELLS THROUGH GRANZYME-DEPENDENT CYTOTOXICITY
2013
-
FEASIBILITY AND SAFETY STUDY OF GBM STEM CELL TUMOR AMPLIFIED RNA IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA
2013
-
NEUROCOGNITIVE DYSFUNCTION IN NEWLY DIAGNOSED HIGH-GRADE GLIOMA PATIENTS: UTILIZATION OF STANDARDIZED COMPUTERIZED NEUROCOGNITIVE TESTING
2013
-
PD-0332991, A CDK4/6 INHIBITOR, SIGNIFICANTLY PROLONGS SURVIVAL IN A GENETICALLY ENGINEERED MOUSE MODEL OF BRAINSTEM GLIOMA
2013
-
PHASE 1 STUDY OF AN ONCOLYTIC POLIO/RHINOVIRUS RECOMBINANT (PVSRIPO) AGAINST RECURRENT GLIOBLASTOMA
2013
-
TARGETING IDH1 MUTATIONS USING PEPTIDE VACCINES IN BRAIN TUMORS
2013
-
A PHASE I/II STUDY OF ADOPTIVE T-CELL THERAPY (ALT) AND DC VACCINATION (DCV) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION (HDC plus ASCR) OR NON-MYELOABLATIVE CONDITIONING (NMA) IN PATIENTS (PTS) WITH RECURRENT CENTRAL PNETS (RE-MATCH PROTOCOL)
2013
-
ABC TRANSPORTERS, ABCG2 AND MDR, LIMIT THE EFFICACY OF DASATINIB IN A DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) MOUSE MODEL.
2013
-
ABERRANT Otx2 EXPRESSION ENHANCES MIGRATION AND INDUCES ECTOPIC PROLIFERATION OF HINDBRAIN NEURONAL PROGENITOR CELLS
2013
-
DEVELOPMENT OF A FIVE-GENE HEDGEHOG SIGNATURE AS A PATIENT PRESELECTION TOOL FOR HEDGEHOG PATHWAY-TARGETED THERAPY IN MEDULLOBLASTOMA
2013
-
DEVELOPMENT OF A NOVEL SMALL MOLECULE INHIBITOR OF SMOOTHENED FOR MEDULLOBLASTOMA TREATMENT
2013
-
DEVELOPMENT OF A NOVEL, SINGLE-CHAIN, TRISPECIFIC IMMUNOTOXIN, D2C7-Mel-14-PE38KDEL FOR TARGETED PEDIATRIC BRAIN TUMOR THERAPY
2013
-
DEVELOPMENTALLY REGULATED ANTIGENS FOR IMMUNOLOGIC TARGETING OF MEDULLOBLASTOMA SUBTYPES
2013
-
ESTABLISHMENT OF SEVEN NEW PERMANENT PEDIATRIC BRAIN TUMOR LINES
2013
-
GENERATION OF ANTI-PDGFR alpha IMMUNOTOXINS FOR BRAINSTEM GLIOMA TREATMENT
2013
-
GLOBAL IDENTIFICATION OF MLL2-TARGETED LOCI REVEALS MLL2'S ROLE IN DIVERSE SIGNALING PATHWAYS
2013
-
H3.3 K27M ACCELERATES PDGF-INDUCED BRAINSTEM GLIOMAGENESIS IN VIVO
2013
-
NOVEL ROLE FOR ENHANCING IMMUNOTHERAPY AGAINST PEDIATRIC BRAIN TUMORS USING HEMATOPOIETIC STEM CELLS
2013
-
ONCOLYTIC POLIOVIRUS IMMUNOTHERAPY OF PRIMARY CNS TUMORS
2013
-
RADIOPROTECTION OF BRAIN WHITE MATTER BY THE CATALYTIC MnSOD MIMIC/ANTIOXIDANT, BMX-001
2013
-
RNA NANOPARTICLE VACCINES RE-DIRECT HOST-IMMUNITY AGAINST INTRACRANIAL MALIGNANCIES
2013
-
A NOVEL PATIENT-SPECIFIC MODEL OF GLIOMA GROWTH KINETICS ELUCIDATES UNDERLYING BIOLOGY AS MEASURED BY GENE EXPRESSION MICROARRAY
2012
-
A PHASE I TRIAL OF MK-0752 IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY CNS MALIGNANCIES: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY
2012
-
A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN MALIGNANT GLIOMA PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB
2012
-
ADOPTIVE CELLULAR THERAPY TARGETING RECURRENT MEDULLOBLASTOMA AND PRIMITIVE NEUROECTODERMAL TUMORS AFTER MYELOABLATIVE AND NON-MYELOABLATIVE CONDITIONING
2012
-
ASSESSMENT OF INTRATUMORAL TREGS AND CLINICAL OUTCOMES IN PRIMARY AND RECURRENT GLIOBLASTOMA
2012
-
BEVACIZUMAB GIVEN WITH TEMOZOLOMIDE AND RADIATION THERAPY (RT) IN NEWLY DIAGNOSED PATIENTS WITH GLIOBLASTOMA MULTIFORME (GBM) REDUCES THE CHANCE OF EARLY RADIOLOGIC PROGRESSION
2012
-
DENDRITIC CELL VACCINES TARGETING HUMAN CYTOMEGALOVIRUS IN GLIOBLASTOMA REVEAL LYMPH NODE HOMING AS A MAJOR AXIS FOR CLINICAL INTERVENTION
2012
-
DEVELOPING RNA NANOPARTICLE VACCINES TARGETING PEDIATRIC AND ADULT BRAIN TUMORS
2012
-
DEVELOPMENT OF IMMUNOCOMPETENT SYNGENEIC MODELS OF MEDULLOBLASTOMA FOR EVALUATION OF IMMUNOTHERAPY
2012
-
EFFECTS OF CONCURRENT AND ADJUVANT BEVACIZUMAB ON THE RISK OF RADIATION NECROSIS FOLLOWING RADIOSURGERY FOR RECURRENT GLIOMA
2012
-
EVIDENCE OF INTERACTION BETWEEN HER2 AND ESTROGEN/PROGESTERONE (ER/PR) RECEPTOR STATUS IN PATIENTS WITH BREAST CANCER AND BRAIN METASTASES
2012
-
EX VIVO GENERATION OF CENTRAL MEMORY-LIKE ANTI-TUMOR T CELLS TO TREAT MALIGNANT BRAIN TUMORS
2012
-
EZN-2208, A NOVEL PEGYLATED SN38 DRUG CONJUGATE, MARKEDLY INHIBITS TUMOR GROWTH IN COMPARISON TO IRINOTECAN
2012
-
FEASIBILITY OF AMPLIFIED CD133((+)) BRAIN TUMOR STEM CELL RNA-PULSED DENDRITIC CELLS FOR THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA
2012
-
INTRAVENOUS TREATMENT WITH AN ENDOTHELIAL GROWTH FACTOR RECEPTOR VIII-TARGETED BISPECIFIC ANTIBODY SUCCESSFULLY TREATS WELL-ESTABLISHED BRAIN TUMORS
2012
-
LONG-TERM FOLLOW-UP OF A PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
2012
-
LONG-TERM SURVIVORSHIP IN PRIMARY GLIOBLASTOMA: A FOCUS ON NEUROCOGNITION
2012
-
LONG-TERM SURVIVORSHIP IN PRIMARY GLIOBLASTOMA: A FOCUS ON QUALITY OF LIFE
2012
-
MYELOABLATIVE TEMOZOLOMIDE INCREASES ANTIGEN-SPECIFIC CD8(+) T-CELL VACCINE RESPONSES AND IS REQUIRED FOR EFFICACIOUS IMMUNOTHERAPY AGAINST INTRACEREBRAL TUMORS
2012
-
NEUROKININ-1 RECEPTOR: A POTENTIAL TARGET TO INHIBIT PEDIATRIC GLIOBLASTOMAS
2012
-
NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH GLIADEL (R) FOLLOWED BY RADIATION THERAPY (RT), TEMOZOLOMIDE AND BEVACIZUMAB, AND POST-RT BEVACIZUMAB AND TEMOZOLOMIDE: A PHASE II STUDY
2012
-
NICHE DERIVED EXTRACELLULAR MATRIX CUES ARE PIVOTAL FOR GLIOBLASTOMA STEM CELL GROWTH AND MAINTENANCE
2012
-
PHASE II TRIAL OF UPFRONT BEVACIZUMAB WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE AND ORAL TOPOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
2012
-
ROLE OF HEMATOPOIETIC STEM CELLS IN ENHANCING THE ANTI-TUMOR EFFICACY OF ADOPTIVE CELLULAR THERAPY
2012
-
TARGETING CYTOMEGALOVIRUS ANTIGENS FOR GLIOBLASTOMA IMMUNOTHERAPY
2012
-
VORINOSTAT, BEVACIZUMAB, AND METRONOMIC TEMOZOLOMIDE FOR RECURRENT HIGH-GRADE GLIOMA: A PHASE I/II CLINICAL TRIAL
2012
-
EFFICACY OF COMBINATION THERAPY WITH PONATINIB (AP24534) +/- BEVACIZUMAB AGAINST PEDIATRIC GLIOBLASTOMA
2012
-
HIGH THROUGHPUT IN VITRO DRUG SCREEN TO IDENTIFY NOVEL THERAPEUTIC TARGETS FOR DIFFUSE INTRINSIC PONTINE GLIOMA
2012
-
RHABDOID TUMOUR SUPPRESSOR SMARCB1: EVIDENCE FOR A ROLE IN THE POST-TRANSCRIPTIONAL REGULATION OF NF2
2012
-
A METANALYSIS OF ALTERNATIVE SCHEDULE OF TEMOZOLOMIDE (TMZ) IN RECURRENT MALIGNANT GLIOMA (MG)
2011
-
CHEMORADIATION-INDUCED THROMBOCYTOPENIA IMPACTS MORBIDITY AND MORTALITY IN NEWLY-DIAGNOSED HIGH-GRADE GLIOMA PATIENTS
2011
-
CYTOMEGALOVIRUS-SPECIFIC IMMUNE DEFICITS IN PATIENTS WITH GBM
2011
-
SMARCB1 MANIPULATION AND EPIGENETIC PROFILING IN ATYPICAL TERATOID RHABDOID TUMORS (ATRTs) PROVIDES NOVEL INSIGHTS INTO TUMOR ETIOLOGY
2011
-
THE EFFECT OF TUMOR SUBTYPE ON SURVIVAL AND THE GRADED PROGNOSTIC ASSESSMENT (GPA) FOR PATIENTS WITH BREAST CANCER AND BRAIN METASTASES
2011
-
A BISPECIFIC T-CELL ENGAGER EFFECTIVELY ERADICATES EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION VARIANT III (EGFRvIII)-EXPRESSING GLIOBLASTOMA MULTIFORME
2011
-
ADOPTIVE CELLULAR THERAPY DURING RECOVERY FROM TREATMENT-INDUCED LYMPHOPENIA IN PEDIATRIC PATIENTS WITH RECURRENT MEDULLOBLASTOMA AND PNETs
2011
-
CANDIDATE HEDGEHOG/SMOOTHENED INHIBITORS FOR PEDIATRIC MEDULLOBLASTOMA
2011
-
CHEMICAL SCREEN FOR PROLIFERATION AND MIGRATION EFFECTS ON SVZ NEURAL STEM CELLS AND BRAIN TUMOR CELLS
2011
-
CONSTRUCTION OF A NOVEL ANTIPODOPLANIN (NZ-1) IMMUNOTOXIN FOR BRAIN TUMOR THERAPY
2011
-
DOES TUMOR MICROVASCULATURE IMPACT RESPONSE TO BEVACIZUMAB IN COMBINATION WITH TEMOZOLOMIDE AGAINST BRAIN TUMOR XENOGRAFTS?
2011
-
EFFICACY OF AP24534 (PONATINIB) +/- BEVACIZUMAB AGAINST PEDIATRIC GLIOBLASTOMA
2011
-
EFFICACY OF BEVACIZUMAB +/- TEMOZOLOMIDE AGAINST PEDIATRIC GLIOMAS
2011
-
EGFR AND EGFRvIII UNDERGO STRESS- AND EGFR KINASE INHIBITOR-INDUCED MITOCHONDRIAL TRANSLOCALIZATION IN GLIOBLASTOMA: A POTENTIAL MECHANISM OF EGFR- AND EGFRvIII-DRIVEN ANTAGONISM OF APOPTOSIS AND DRUG RESPONSE
2011
-
ESTABLISHMENT OF AND PROOF OF CONCEPT FOR A HUMAN PEDIATRIC BRAINSTEM GLIOMA XENOGRAFT MODEL
2011
-
GAIN-OF-FUNCTION tGLI1 TRANSCRIPTION FACTOR AUGMENTS ANCHORAGE-INDEPENDENT GROWTH OF MEDULLOBLASTOMA CELLS AND CONFERS THEIR RESISTANCE TO SMO INHIBITORS
2011
-
GANGLIOSIDE EXPRESSION IN PEDIATRIC BRAIN TUMOR CELL LINES AND DEVELOPMENT OF ANTIGANGLIOSIDE scFv BY AFFINITY MATURATION
2011
-
INHIBITION OF TUMOR GROWTH IN PEDIATRIC BRAIN TUMOR XENOGRAFTS TREATED WITH LBH589 (PANOBINOSTAT)
2011
-
MAPPING MONOCILIATED AND MULTICILIATED FOURTH VENTRICULAR WALL CELLS AS THE ORIGIN OF CLASSIC PEDIATRIC MEDULLOBLASTOMAS
2011
-
MEL-14 AND 9.2.27 IMMUNOTOXINS: PROMISING THERAPEUTICS FOR PEDIATRIC GLIOMA
2011
-
METABOLOMIC PROFILING OF A GLIOMA CELL LINE EXPRESSING IDH1 AND IDH2 MUTANTS
2011
-
OTX2 IS A PREVALENT BUT TARGETABLE ONCOGENE IN Shh-INDEPENDENT MEDULLOBLASTOMAS
2011
-
TARGETED RADIOTHERAPY OF MEDULLOBLASTOMA USING SOMATOSTATIN RECEPTOR AVID RADIOLABELED PEPTIDES
2011
-
THE GENETIC LANDSCAPE OF MEDULLOBLASTOMA
2011
-
UPREGULATION OF VEGF-A GENE EXPRESSION BY THE tGLI1 TRANSCRIPTION FACTOR CONTRIBUTES TO GLIOBLASTOMA ANGIOGENESIS
2011
-
A RETROSPECTIVE STUDY OF PATIENTS WITH MELANOMA BRAIN METASTASES RECEIVING CONCURRENT WHOLE BRAIN RADIATION AND TEMOZOLOMIDE
2011
-
A PHASE I/II STUDY OF VORINOSTAT PLUS DAILY TEMOZOLOMIDE AND BEVACIZUMAB IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA
2010
-
ACTIVITY OF GMX1777 AGAINST A PANEL OF BRAIN TUMOR XENOGRAFTS
2010
-
ADDITION OF GBM HISTOLOGICAL FEATURES AND EGFRVIII EXPRESSION TO THE CANCER GENOME ATLAS: PHENOTYPIC CORRELATES OF MOLECULAR SUBCLASSES
2010
-
CHARACTERIZATION OF LONG-TERM SURVIVORS OF PRIMARY GLIOBLASTOMA MULTIFORME AND THEIR USE OF PSYCHOACTIVE MEDICATIONS
2010
-
DASATINIB (SPRYCEL) AND ERLOTINIB (TARCEVA) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA: A PHASE 1 TRIAL
2010
-
DIFFERENTIAL EXPRESSION OF FULL-LENGTH AND TRUNCATED NEUROKININ 1 RECEPTORS IN GLIOBLASTOMA CELLS
2010
-
EFFICACY OF LBH589 (PANOBINOSTAT) AGAINST A PANEL OF PEDIATRIC BRAIN TUMOR XENOGRAFTS
2010
-
FINAL RESULTS OF A PHASE II STUDY OF IMATINIB MESYLATE (GLEEVEC) PLUS HYDROXYUREA FOR ADULTS WITH RECURRENT/PROGRESSIVE LOW-GRADE GLIOMA
2010
-
GENOME-WIDE PROFILING OF PAEDIATRIC CNS TUMOR XENOGRAFTS BY EXPRESSION AND HIGH-RESOLUTION CGH MICROARRAYS
2010
-
PHASE II TRIAL OF CONTINUOUS LOW-DOSE TEMOZOLOMIDE (TMZ) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA (MG) WITH AND WITHOUT PRIOR EXPOSURE TO BEVACIZUMAB (REV)
2010
-
RETROSPECTIVE ANALYSIS OF INSOMNIA IN RECURRENT GLIOMA PATIENTS AND ITS ASSOCIATION WITH DEXAMETHASONE AND ANTI-EPILEPTICS
2010
-
SURVIVAL AND TOXICITY UPDATE OF THE PHASE 2 TRIAL OF BEVACIZUMAB (BV) IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM) PATIENTS
2010
-
SURVIVAL AND TREATMENT OF CRANIAL METASTASES (CMS) FROM NEUROENDOCRINE TUMORS (NETS) AT MEMORIAL SLOAN-KETTERING CANCER CENTER (MSKCC)
2010
-
UNDERSTANDING AND TARGETING KINASE-INDEPENDENT ACTIVITY OF EGFR AND EGFRVIII TO OVERCOME GBM DRUG RESISTANCE
2010
-
USE OF BIOCHEMOTHERAPY AND STEREOTACTIC RADIOSURGERY IN THE MANAGEMENT OF RECURRENT MALIGNANT GLIOMA
2010
-
DEVELOPMENTAL AND FUNCTIONAL OUTCOME FOLLOWING POST-OPERATIVE CHEMOTHERAPY AND LOCAL CONFORMAL RADIATION IN INFANTS WITH MEDULLOBLASTOMA USING A CENTRALLY ADMINISTERED PHONE BASED INTERVIEW TECHNIQUE, FOLLOW UP REPORT: A CHILDRENS ONCOLOGY GROUP STUDY
2010
-
EXPLORING THE FEASIBILITY OF EPIGENETIC THERAPIES FOR RHABDOID TUMOR
2010
-
FATIGUE SYMPTOMS IN SURVIVORS OF CHILDHOOD CANCER: A COMPARISON OF PATIENT AND PARENT REPORT
2010
-
GENETIC PROFILING IN TUMOUR XENOGRAFTS FROM PAEDIATRIC GLIOMAS BY EXPRESSION AND HIGH RESOLUTION COMPARATIVE GENOMIC HYBRIDISATION MICROARRAYS
2010
-
HOW DO PARENTS COPE WITH THEIR CHILD'S DIAGNOSIS AND TREATMENT OF AN EMBRYONAL TUMOR? RESULTS OF A PROSPECTIVE AND LONGITUDINAL STUDY
2010
-
IDENTIFYING OBSTACLES IN TREATING CHILDREN WITH PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS IN DEVELOPING COUNTRIES
2010
-
PLEOMORPHIC XANTHOASTROCYTOMA IN CHILDHOOD
2010
-
RADIATION THERAPY AND ADJUVANT CHEMOTHERAPY IN A PATIENT WITH A HIGH GRADE GLIOMA AND UNDERLYING ATAXIA TELANGIECTASIA
2010
-
RISK-ADAPTED CRANIOSPINAL RADIOTHERAPY FOLLOWED BY HIGH DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM CELL RESCUE IN CHILDREN WITH LARGE CELL/ANAPLASTIC MEDULLOBLASTOMA: RESULTS FROM ST. JUDE MEDULLOBLASTOMA 96 (SJMB96) AND ST. JUDE MEDULLOBLASTOMA 03 (SJMB03)
2010
-
A PHASE I STUDY OF SUNITINIB PLUS IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT MALIGNANT GLIOMA
2009
-
A RETROSPECTIVE SINGLE INSTITUTIONAL ANALYSIS OF CILENGITIDE (CGT) AND CHEMOTHERAPY FOR HEAVILY PRETREATED RECURRENT GLIOBLASTOMA MULTIFORME (GBM)
2009
-
BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II TRIAL
2009
-
BEVACIZUMAB PLUS ERLOTINIB IN RECURRENT HIGH-GRADE GLIOMA: A PHASE II TRIAL
2009
-
DIRECT TYROSINE PHOSPHORYLATION OF GSTP1 BY EGFR INDUCES JNK ACTIVATION IN GLIOBLASTOMA CELLS
2009
-
GENETIC DIVERSITY ASSOCIATED WITH SURVIVAL IN MALIGNANT GLIOMAS IDENTIFIED BY LINKAGE DISEQUILIBRIUM-BASED ANALYSIS OF HAPLOTYPE BLOCK REGIONS OF DNA REPAIR GENES
2009
-
PHASE I STUDY OF VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA
2009
-
PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT MALIGNANT GLIOMA PATIENTS: FINAL STUDY RESULTS
2009
-
A PHASE II SINGLE-ARM TRIAL OF PALONOSETRON (PALO) FOR THE PREVENTION OF ACUTE AND DELAYED CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN MALIGNANT GLIOMA (MG) PATIENTS RECEIVING IRINOTECAN IN COMBINATION WITH BEVACIZUMAB
2009
-
CTLA-4 BLOCKADE AUGMENTS VACCINE-INDUCED ANTITUMOR IMMUNITY AGAINST INTRACRANIAL GLIOMA
2009
-
A PHASE II STUDY OF BEVACIZUMAB PLUS ETOPOSIDE AMONG RECURRENT MALIGNANT GLIOMA PATIENTS
2009
-
BEVACIZUMAB (BV) IN COMBINATION TO TEMOZOLOMIDE (TMZ) AND RADIATION THERAPY (RT) FOLLOWED BY BV, TMZ, AND IRINOTECAN (CPT-11) FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM): A PHASE 2 TRIAL
2009
-
SUNITINIB PLUS IRINOTECAN FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA: A PHASE I TRIAL
2009
-
VANDETANIB, IMATINIB MESYLATE, AND HYDROXYUREA FOR RECURRENT MALIGNANT GLIOMA: A PHASE I STUDY
2009
-
ABSENCE OF EVIDENCE IS NO EVIDENCE OF ABSENCE
2008
-
AN UPDATE ON THE EFFECTS OF NEURADIAB ON PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
2008
-
BEVACIZUMAB IN COMBINATION WITH TEMOZOLOMIDE AND RADIATION THERAPY FOLLOWED BY BEVACIZUMAB, TEMOZOLOMIDE, AND IRINOTECAN FOR NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME
2008
-
CONSTITUTIVE STAT3 ACTIVATION FREQUENTLY COEXISTS WITH EGFR EXPRESSION IN HIGH-GRADE GLIOMAS AND TARGETING STAT3 SENSITIZES THEM TO ANTI-EGFR AND ALKYLATING AGENTS
2008
-
DOSIMETRIC AND RADIOBIOLOGICAL IMPACT OF A HIGH-DEFINITION MICROMULTILEAF COLLIMATOR ON RADIOSURGERY OF VESTIBULAR SCHWANNOMAS
2008
-
EFFICACY AND IMMUNOLOGIC EFFECTS OF RNA-PULSED DENDRITIC CELL VACCINES TARGETING HUMAN CYTOMEGALOVIRUS ANTIGENS IN PATIENTS WITH GLIOBLASTOMA
2008
-
GENOMIC LANDSCAPE OF GLIOBLASTOMA
2008
-
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF THE HUMAN GSTP1 GENE AS A NOVEL TRANSCRIPTIONAL TARGET OF THE P53 TUMOR SUPPRESSOR GENE
2008
-
IDENTIFICATION OF MICROBIAL DNAS IN BRAIN TUMORS
2008
-
LIGAND-DEPENDENT ACTIVATION OF THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INDUCES EARLY DRUG RESISTANCE IN BRAIN TUMOR CELLS VIA ACTIVATION OF ITS DOWNSTREAM TARGET GLUTATHIONE S-TRANSFERASE P1
2008
-
MIR-124 INHIBITS CDK6 AND INDUCES G(1) CELL CYCLE ARREST IN MEDULLOBLASTOMA CELLS
2008
-
THE POSITIVE INFLUENCE OF TEMOZOLOMIDE ON THE HUMORAL AND CELL-MEDIATED (DTH) RESPONSES TO EGFRVIII-TARGETED VACCINE (CDX-110) IN PATIENTS WITH GBM
2008
-
ANZCCSG babybrain 99: Intensified systemic chemotherapy, second look surgery, and involved field radiation in young children with CNS malignancy
2008
-
Developmental and functional outcome following postoperative chemotherapy and local conformal radiation in infants with medulloblastoma using a centrally administered phone-based interview technique, initial report: A children's oncology group study
2008
-
Dual-specific antibody, D2C7 (SCDSFV)-PE38KDEL for brain tumor therapy
2008
-
Establishment and characterization of cell lines and transplantable xenografts from pediatric brain tumors
2008
-
Ganglioside expression in pediatric brain tumor xenograft lines
2008
-
Identification of antigens on cancer stem cells for brain tumor therapy
2008
-
In vivo bioluminescence imaging of luciferase-expressing pediatric brain tumor xenografts in rodent models
2008
-
Insights into the epigenetics of atypical teratoid rhabdoid tumors: The potential for treatment with histone deacetylase inhibitors
2008
-
P9934: Systemic chemotherapy, secondlook surgery and conformal radiation therapy limited to the posterior fossa and primary site for children > 8 months and < 3 years with nonmetastatic medulloblastoma: A children's oncology group phase III study
2008
-
The oncogenic role of OTX2 in medulloblastoma pathogenesis and its clinical implications as a tumor marker and therapeutic target
2008
-
PHASE II TRIAL OF CONTINUOUS LOW-DOSE TEMOZOLOMIDE FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA
2008
-
Characterization of brain tumor exosomes: Biology, biochemistry, immumology
2007
-
Deregulation of an extraordinarily important developmental gene promotes medulloblastoma tumorigenesis
2007
-
Efficacy of dronabinol for nausea, vomiting, and appetite disturbances in adult patients with primary malignant gliomas
2007
-
Evaluation of tumor response by dynamic contrast-enhanced magnetic resonance imaging in glioblastoma (gbm) patients treated with bevacizumab (bev) and irinotecan (CPT-11)
2007
-
Identification of known and novel recurrent amplified oncogenes in pediatric medulloblastoma
2007
-
In vivo characterization of the blood-brain and blood-tumor barrier in orthotopic xenograft tumors derived from adult and pediatric malignant gliomas
2007
-
Multiple recurrent genetic events converge on proper control of histone 3 lysine 9 methylation in pediatric medulloblastoma
2007
-
Phase II trial of Zoledronic Acid (ZA) for bone loss prevention in glioma patients
2007
-
RNA-loaded dendritic cells targeting cytomegalovirus in patients with malignant glioma
2007
-
Stat3 constitutive activation is associated with glioma tumor grade: Pathway profiling and therapy
2007
-
Targeting constitutively activated stat3 sensitizes medulloblastomas to chemotherapeutic agents
2007
-
Targeting hedgehog signaling in medulloblastoma
2007
-
Temozolomide therapy induces an increase in regulatory T-cells without abbrogating a specific tumor
2007
-
Low caspase-8 expression levels will preclude meaningful death ligand therapy in malignant glioma
2007
-
Phase I trial of oral temozolomide and intravenous O-6-benzylguanine (O-6-BG), a methylguanine methyltransferase inhibitor, in pediatric patients with recurrent brain tumors
2007
-
Pilot phase II study of metrenomic oral cyclophosphamide plus thalidomide in children with recurrent malignant brain tumors
2007
-
Risk of stroke among long-term survivors of childhood brain tumors: A report from the childhood cancer survivor study
2007
-
Temozolomide as second-line chemotherapy for progressive low-grade glioma in children
2007
-
The impact of childhood brain tumors on families: A longitudinal study
2007
-
Tumor histology is an important independent prognostic factor of event-free survival in average-risk and high-risk medulloblastoma: Results from a prospective collaborative trial (SJMB 96)
2007
-
A novel low-molecular-weight inhibitor of focal adhesion kinase, inhibits glioma growth
2006
-
A phase I trial of imatinib (GLEEVEC), hydroxyurea and RAD001 for patients with recurrent malignant glioma
2006
-
AAL881, a novel small molecule inhibitor of RAF and VEGFR activities, blocks growth of malignant glioma
2006
-
Bevacizumab and irinotecan is an effective treatment for malignant gliomas
2006
-
Characterizing genomic rearrangements in oligodendroglioma using whole genome tilepath hrCGH arrays
2006
-
Development of the duke cancer cognitions inventory-brain tumor version (DCCI-BT)
2006
-
Exposure assessment methodology in a brain cancer epidemiology study
2006
-
Fatigue in adolescent survivors of pediatric cancer
2006
-
Glioma cancer stem cells promote tumor angiogenesis through vascular endothelial growth factor
2006
-
Glutathione S-transferase P1 (GSTP1) is a novel downstream target of Akt in human gliomas
2006
-
Hydrocephalus as an additional risk factor for academic and intellectual outcome in survivors of pediatric medulloblastoma treated with radiation
2006
-
Neurocognitive deficits according to hemisphere and diagnosis among patients with high-grade CNS tumors
2006
-
Overall survival of primary glioblastoma (GBM) patients receiving radiation and concurrent temozolomide followed by rotational multi-agent chemotherapy
2006
-
Parent and family psychosocial adjustment as a function of pediatric tumor type
2006
-
Patient-specific murine I-131-labeled anti-tenascin monoclonal antibody 81C6 radioimmunotherapy for delivering a 44-GY boost to the resection cavity periphery of patients with newly diagnosed primary malignant brain tumors: A feasibility pilot study
2006
-
Phase I trial of Temodar plus O-6-benzylguanine 5-day regimen for patients with progressive glioblastoma multiforme
2006
-
Phase I trial of temozolomide plus dose-escalating imatinib mesylate for patients with malignant glioma
2006
-
Polymorphism of the promoter of the epidermal growth factor (EGF) gene in patients, its distribution and correlation with survival in glioma patients
2006
-
Secreted protein acidic and rich in cysteine (SPARC) induces glioma invasion and survival through activation of focal adhesion kinase and integrin-linked kinase
2006
-
The combination of novel low-molecular-weight inhibitors of Raf (LBT 613) and TOR (RAD001, everolimus) decreases glioma proliferation and invasion
2006
-
A novel mechanism of PKA- and PKC-dependent drug resistance in human gliomas involving phosphorylation and metabolic activation of glutathione S-transferase P1 (GSTP1)
2005
-
An update of phase 2 trial results: Patients with recurrent malignant glioma treated with iodine 131-labeled murine antitenascin monoclonal antibody 81C6 into the resection cavity
2005
-
Caspase-8 status of ex vivo gliomas
2005
-
Comination of imatinib mesylate (STI-571, Gleevec) and temozolomide (temodar) displays increased activity against glioma xenografts
2005
-
Enhanced cellular retention of an internalizing anti-EGFRvIII monoclonal antibody radioiodinated using LYS5-[*I]iodobenzoyl Gly(1)-maleimido GEEEK ([*I]IB-Mal-D-GEEEK), a prosthetic group containing negatively charged D-glutamates
2005
-
Expression levels of the transforming growth factor-beta mediator SMAD3 determines glioma phenotype in a genetically defined human glioma model and a transgenic murine glioma model
2005
-
GPNMB: A new target for human high-grade gliomas (HGL) immunotherapy
2005
-
Gene expression profiling links invasion-related genes to poor survival in older glioblastoma patients
2005
-
Imatinib mesylate (Gleevec) plus hydroxyurea: An effective regimen in the treatment of recurrent malignant glioma: Phase 2 study results
2005
-
Immunologic targeting of the tumor-specific antigen contained in the deletion mutation of the epidermal growth factor receptor (EGFRvIII) with peptide loaded dendritic cells in patients with malignant gliomas
2005
-
Low-molecular-weight EGFR/KDR tyrosine kinase inhibitor offers combinatorial benefit with a rapamycin derivative based on PTEN status
2005
-
Non-pathogenic poliovirus recombinants for the treatment of malignant glioma
2005
-
PIK3CA is mutated in oligodendrogliomas, astrocytomas, and medulloblastomas and associated with chromosome 1p, 19q LOH in oligodendrogliomas
2005
-
Phase I study results of Gefitinib (iressa; ZD1839) plus rapamycin in the treatment of patients with recurrent malignant glioma
2005
-
Phase II study of cloretazine for the treatment of adults with recurrent malignant glioma
2005
-
Pre-clinical evaluation of D2C7, a monoclonal antibody reactive for both the wild type and variant III mutant epidermal growth factor receptor, for radioimmunotherapy of malignant gliomas
2005
-
Prevalence and prognostic significance of polymorphisms at the glutathione S-transferase M1, M3, P1, and T1 gene loci in human astrocytomas
2005
-
Quality of life in pediatric brain tumor survivors
2005
-
Targeting malignant gliomas with a low-molecular-weight Raf/vascular endothelial growth factor receptor inhibitor
2005
-
Temozolomide (TMZ) with O6-benzylguanine (BG) for TMZ-resistant malignant glioma: A phase 2 trial
2005
-
Temozolomide (TMZ) with O6-benzylguanine (BG) plus CPT-11 in the treatment of recurrent malignant glioma: A phase I trial
2005
-
The PTEN tumor suppressor gene shifts cellular responses to transforming growth factor-beta towards tumor suppression in malignant gliomas
2005
-
VEGF cooperates with secreted protein acidic and rich in cysteine (SPARC) to activate intracellular glioma survival pathways
2005
-
Anzccsg baby B99: Systemic chemotherapy, second-look surgery and involved field radiation for children less than four years of age with malignant central nervous system tumours
2004
-
Convection-enhanced delivery of IL13-PE38QQR in malignant glioma: Comparison of observed and predicted drug distribution
2004
-
Dendritic cell vaccine for intracranial tumors I (DC Victori trial)
2004
-
Detection and immunologic recognition of cytomegalovirus antigens expressed within malignant gliomas
2004
-
Evaluating impact of symptom management on quality of life in glioma patients
2004
-
Extraosseous Ewings sarcoma (EES) of the central nervous system (CNS) - Case reports and molecular diagnosis
2004
-
Immunotherapeutic target antigen phenotypes of pediatric vs. adult central nervous system (CNS) tumor biopsies, xenografts, and cultured cells
2004
-
Incidence and patterns of neuraxis metastasis (NM) in patients (PTS) with diffuse pon'ine glioma (DPG)
2004
-
Inhibition of receptor tyrosine kinases and mammalian target of rapamycin offers combinatorial benefit in tumor control
2004
-
Medulloblastoma neoplastic meningitis targeted radiotherapy with intrathecal alpha-emitter At-211-labeled thymidine analogue
2004
-
Molecular genomics of medulloblastoma
2004
-
Monoclonal antibodies (MABS) against somatostatin receptor 2A (SSTR2A) as potential medulloblastoma therapeutic reagents
2004
-
Oligoastrocytoma/oligodendroglioma in association with dysembryoplastic neuroepithelial tumor (DNET)
2004
-
Phase I trial of adults with primary malignant glioma with irinotecan (CPT-11) plus temozolomide (Temodar)
2004
-
Phase I trial of temozolomide (Temodar) plus irinotecan (CPT-11) plus O6-benzylguanine (O6-BG) in the treatment of recurrent or progressive cerebral anaplastic gliomas
2004
-
Phase II study of 131-iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (M81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors
2004
-
Phase II study of oral temozolomide (TMZ) in children with progressive low-grade gliomas (LGG)
2004
-
Phase II trial of imatinib mesylate plus hydroxyurea in the treatment of patients with malignant glioma
2004
-
Phase II trial of temozolomide (Temodar) plus O6-benzylguanine (O6-BG) in the treatment of patients with Temodar-resistant malignant glioma
2004
-
Phase II upfront CPT-11 plus celecoxib for adults with glioblastoma multiforme
2004
-
Preliminary evidence of nonverbal learning disability in survivors of pediatric brain tumors
2004
-
SB-431542, a small molecule transforming growth factor-B-receptor antagonist, inhibits human glioma cell line proliferation and motility
2004
-
Somatostatin targeted radiotherapeuiccs for medulloblastoma
2004
-
Theoretical estimation of dermal exposure to known and suspected animal neurocarcinogens
2004
-
ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, inhibits growth of multiple primary central nervous system tumor types
2004
-
Bevacizumab, radiation therapy (RT) and temozolomide followed by bevacizumab and temozolomide with continuation of bevacizumab beyond progression: A phase II trial.
-
QOL-20. Low-dose Naltrexone in newly diagnosed high-grade glioma: placebo-controlled, double-blind, randomized pilot study.
-
QOL-21 Diet and health-related quality of life (HRQoL) in the primary brain tumor population.